Luffer-Atlas D - Search Results

1

Identification of 4-Aminopyrazolopyrimidine Metabolite That May Contribute to the Hypolipidemic Effects of LY2584702 in Long Evans Diet-Induced Obese Rats.

Estridge TB, Dey AB, Reidy C, Yu X, Zhang Y, Hartley M, Milligan PL, Jin N, Kowala MC, Leohr JK, Fretland AJ, Mabry TE, Luffer-Atlas D, Luo MJ. Estridge TB, et al. Among authors: luffer atlas d. J Pharmacol Exp Ther. 2017 Jul;362(1):108-118. doi: 10.1124/jpet.117.240242. Epub 2017 May 2. J Pharmacol Exp Ther. 2017. PMID: 28465372

2

Serum Lipid and Protein Changes in Healthy Dyslipidemic Subjects Given a Selective Inhibitor of p70 S6 Kinase-1.

Leohr JK, Luffer-Atlas D, Luo MJ, DeBrota DJ, Green C, Mabry TE, Suico JG. Leohr JK, et al. Among authors: luffer atlas d. J Clin Pharmacol. 2018 Apr;58(4):412-424. doi: 10.1002/jcph.1032. Epub 2017 Nov 26. J Clin Pharmacol. 2018. PMID: 29178617 Clinical Trial.

3

The effect of hepatic or renal impairment on the pharmacokinetics of edivoxetine, a selective norepinephrine transporter reuptake inhibitor.

Kielbasa W, Tesfaye E, Luffer-Atlas D, Mitchell MI, Turik MA. Kielbasa W, et al. Eur J Clin Pharmacol. 2013 Dec;69(12):2011-9. doi: 10.1007/s00228-013-1572-y. Epub 2013 Aug 17. Eur J Clin Pharmacol. 2013. PMID: 23955175 Free PMC article. Clinical Trial.

4

Overview of metabolite safety testing from an industry perspective.

Anderson S, Knadler MP, Luffer-Atlas D. Anderson S, et al. Bioanalysis. 2010 Jul;2(7):1249-61. doi: 10.4155/bio.10.67. Bioanalysis. 2010. PMID: 21083238 Review.

5

A decade of drug metabolite safety testing: industry and regulatory shared learning.

Luffer-Atlas D, Atrakchi A. Luffer-Atlas D, et al. Expert Opin Drug Metab Toxicol. 2017 Sep;13(9):897-900. doi: 10.1080/17425255.2017.1364362. Epub 2017 Aug 11. Expert Opin Drug Metab Toxicol. 2017. PMID: 28797172 No abstract available.

6

Predicting circulating human metabolites: how good are we?

Anderson S, Luffer-Atlas D, Knadler MP. Anderson S, et al. Chem Res Toxicol. 2009 Feb;22(2):243-56. doi: 10.1021/tx8004086. Chem Res Toxicol. 2009. PMID: 19138063

7

A radiocalibration method with pseudo internal standard to estimate circulating metabolite concentrations.

Yi P, Luffer-Atlas D. Yi P, et al. Bioanalysis. 2010 Jul;2(7):1195-210. doi: 10.4155/bio.10.81. Bioanalysis. 2010. PMID: 21083234

8

Discovery of the First α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antagonist Dependent upon Transmembrane AMPA Receptor Regulatory Protein (TARP) γ-8.

Gardinier KM, Gernert DL, Porter WJ, Reel JK, Ornstein PL, Spinazze P, Stevens FC, Hahn P, Hollinshead SP, Mayhugh D, Schkeryantz J, Khilevich A, De Frutos O, Gleason SD, Kato AS, Luffer-Atlas D, Desai PV, Swanson S, Burris KD, Ding C, Heinz BA, Need AB, Barth VN, Stephenson GA, Diseroad BA, Woods TA, Yu H, Bredt D, Witkin JM. Gardinier KM, et al. Among authors: luffer atlas d. J Med Chem. 2016 May 26;59(10):4753-68. doi: 10.1021/acs.jmedchem.6b00125. Epub 2016 Apr 29. J Med Chem. 2016. PMID: 27067148

9

The early estimation of circulating drug metabolites in humans.

Luffer-Atlas D. Luffer-Atlas D. Expert Opin Drug Metab Toxicol. 2012 Aug;8(8):985-97. doi: 10.1517/17425255.2012.693159. Epub 2012 Jun 10. Expert Opin Drug Metab Toxicol. 2012. PMID: 22681256 Review.

10

Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer.

Mo G, Baldwin JR, Luffer-Atlas D, Ilaria RL Jr, Conti I, Heathman M, Cronier DM. Mo G, et al. Among authors: luffer atlas d. Clin Pharmacokinet. 2018 Mar;57(3):355-365. doi: 10.1007/s40262-017-0562-0. Clin Pharmacokinet. 2018. PMID: 28620891 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

25 results

Search Page